Compare DIN & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | EBS |
|---|---|---|
| Founded | 1958 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.8M | 312.8M |
| IPO Year | 1994 | 2006 |
| Metric | DIN | EBS |
|---|---|---|
| Price | $31.27 | $6.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $36.33 | $11.00 |
| AVG Volume (30 Days) | 512.4K | ★ 960.8K |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $879,300,000.00 | $742,900,000.00 |
| Revenue This Year | $8.75 | N/A |
| Revenue Next Year | $4.72 | $7.03 |
| P/E Ratio | $34.53 | ★ N/A |
| Revenue Growth | ★ 8.25 | N/A |
| 52 Week Low | $23.23 | $4.36 |
| 52 Week High | $39.68 | $14.06 |
| Indicator | DIN | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 42.71 |
| Support Level | $27.55 | $5.50 |
| Resistance Level | $31.89 | $6.60 |
| Average True Range (ATR) | 1.42 | 0.34 |
| MACD | 0.24 | -0.11 |
| Stochastic Oscillator | 51.98 | 15.30 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.